Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 3/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27170983 | 0.88 | KDM4E (0.56) | KMT2AMEN1KDM4EGAANCF1 | |
| SCHEMBL3760506 | 0.83 | TERT (0.50) | KMT2AMEN1TERTIP6K1MAP4K4 | |
| SCHEMBL25746312 | 0.81 | MEN1 (0.48) | KMT2AMEN1TERTIP6K1MAP4K4 | |
| SCHEMBL27170958 | 0.79 | IDO1 (0.41) | KMT2AMEN1KDM4EGAAHTR1A | |
| SCHEMBL20509955 | 0.78 | HTR6 (0.50) | MAP4K4HTR1A | |
| SCHEMBL20509329 | 0.75 | KHK (0.55) | KDM4ENCF1 | |
| SCHEMBL8976481 | 0.75 | IP6K1 (0.68) | TERTIP6K1MAP4K4IP6K3KDM4E | |
| SCHEMBL8871494 | 0.74 | MAP4K4 (0.68) | KMT2AMEN1TERTIP6K1MAP4K4 | |
| SCHEMBL29656652 | 0.74 | IP6K1 (0.45) | KMT2AMEN1IP6K1KDM4EGAA | |
| SCHEMBL14843585 | 0.73 | LMNA (0.56) | KMT2AMEN1KDM4EACHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| EP-3601267-A1 | 2-METHYL-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172250-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | KMT2A 834/4885MEN1 403/4885TERT 3125/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | KMT2A 834/4885MEN1 403/4885TERT 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.